COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00418431
Recruitment Status : Unknown
Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
First Posted : January 4, 2007
Last Update Posted : January 4, 2007
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.

The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Condition or disease Intervention/treatment Phase
Central Serous Chorioretinopathy Drug: Intravitreal injection of Bevacizumab Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : April 2006
Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria

  • Any visual acuity.
  • Central serous chorioretinopathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00418431

Layout table for location contacts
Contact: Mitzy E Torres Soriano, MD 525510841400 ext 1172
Contact: Hugo Quiroz-Mercado, MD 525510841400 ext 1171

Layout table for location information
Asociacion para Evitar la Ceguera en Mexico Recruiting
Mexico DF, DF, Mexico, 04030
Contact: Mitzy E Torres Soriano, MD    5255510841400 ext 1171   
Sub-Investigator: Maura Abraham, MD         
Sub-Investigator: Orlando Ustariz, MD         
Sub-Investigator: Gerardo Garcia Aguirre         
Sub-Investigator: Veronica Kon-Jara, MD         
Sub-Investigator: Hugo Quiroz-Mercado, MD         
Sub-Investigator: Jose L Guerrero, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Layout table for investigator information
Principal Investigator: Mitzy E Torres Soriano, MD Asociación para Evitar la Ceguera en México
Layout table for additonal information Identifier: NCT00418431    
Other Study ID Numbers: APEC-0016
First Posted: January 4, 2007    Key Record Dates
Last Update Posted: January 4, 2007
Last Verified: June 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors